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Abstract 
Conditioned medium (CM) from clonal sub-populations of the pancreatic cancer cell line, 
MiaPaCa-2 with differing invasive abilities, were examined for their effect on in vitro invasion. 
Conditioned medium from Clone #3 (CM#3) strongly promoted invasion, while CM from Clone 
#8 (CM#8) inhibited invasion in vitro. 2D DIGE followed by MALDI-TOF MS analysis of 
CM#3 and CM#8 identified 41 proteins which were differentially regulated; 27 proteins were 
down-regulated and 14 proteins up-regulated in the invasion-promoting CM#3 when compared 
to CM#8. Western blotting analysis confirmed the down-regulated expression of gelsolin and 
the up-regulation of aldehyde dehydrogenase 1A1 in CM#3. Down-regulation of aldehyde 
dehydrogenase 1A1 in Clone #3 CM and gelsolin levels in Clone #8 CM by siRNA transfection 
revealed an important involvement of these proteins in promoting and inhibiting invasion in 
these pancreatic cancer cell lines.  
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1.0 Introduction 
Pancreatic cancer is one of the most lethal cancers and is the 8th leading cause of cancer-related 
deaths in Europe [1]. Pancreatic cancer is associated with poor prognosis, the rate of mortality 
being similar to that of the rate of incidence.  
All-stage 5-year survival rate is less than 5% [2, 3]. Conventional approaches including, 
surgery, radiation, chemotherapy and combinations of these therapies, has had little effect on the 
survival rate of patients diagnosed with pancreatic cancer. Pancreatic cancer appears to be 
inherently resistant to a wide variety of chemotherapeutic agents, which can differ greatly and 
are unrelated with respect to molecular structure and target specificity. The malignant 
progression, invasion and metastasis of this cancer is complex and poorly understood. In this 
study, we investigated the proteomic profile of proteins from the conditioned media of two sub-
clones of a pancreatic cancer cell line with varying in vitro invasive characteristics. Proteins 
released by pancreatic tumour cells may be detectable in bodily fluids such as urine, blood, 
serum and pancreatic ductal juice. Such proteins could be useful in early diagnosis, monitoring 
and perhaps even molecular classification of pancreatic tumours [4]. Proteomic analyses of 
pancreatic tissue, pancreatic juice as well as blood plasma and sera have been reported [5]. The 
main biomarker currently available for pancreatic cancer detection, CA19-9, has been 
demonstrated to be quite sensitive and specific in the diagnosis of this malignancy [6, 7], 
however, this marker is not fully specific as false-positive or false-negative findings occur in 
patients with other gastrointestinal malignancies and also in patients with benign disease, 
particularly when associated with obstructive jaundice or cirrhosis, which may contribute to late 
diagnosis of pancreatic cancer. Approximately 10% of the population with the Lewis negative 
genotype are not able to produce CA 19-9, due to a deficiency in a fucosyltransferase specified 
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by the Le gene that is involved in its synthesis [8]. Therefore, in a sub-set of patients, CA 19-9 
expression will be falsely low even in the presence of advanced pancreatic cancer [9]. 
We previously isolated sub-clones of the human pancreatic adenocarcinoma cell line, MiaPaCa-
2. This cell line was chosen as it displays modest invasion through matrigel, and could be easily 
cultured as single cell colonies. Two sub-clones, Clone #3 and Clone #8 displayed the largest 
differences in invasion compared to the parental cell line and were chose for further analysis. 
In this study, we compared proteins in the conditioned media of highly and poorly invasive sub-
clones of the pancreatic cancer cell line, MiaPaCa-2, and identified many novel up-regulated 
and down-regulated proteins in our model. Furthermore, we investigated the functional role of 
aldehyde dehydrogenase 1A1 and gelsolin in invasion by siRNA analysis and determined that 
these proteins may have a novel role in the invasive phenotype of pancreatic cancer. 
 
2.0 Materials and methods 
2.1 Cell lines 
The human pancreatic cell line MiaPaCa-2 was obtained from the European Collection of Cell 
Cultures (ECACC, UK). BxPc-3, Panc-1 and AsPc-1 human pancreatic cancer cell lines were 
obtained from the American Tissue Culture Collection (ATCC, Rockville, MD, USA). Clone #3 
and Clone #8 were obtained by single cell dilution in this laboratory. Briefly the parental cell 
line, MiaPaCa-2 was diluted to a concentration of 3 cells/ml and 100 µl plated onto each well of 
a 96-well plate. After 24 hours each well was studied for single cells, and allowed to grow into 
colonies. The colonies were then screened by invasion assay to assess their invasive abilities. 
Cells were maintained in a humidified atmosphere containing 5 % CO2 at 37 oC in DMEM 
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supplemented with 5 % FCS (Sigma-Aldrich). All cell lines were free from Mycoplasma as 
tested with the indirect Hoechst staining method. 
 
2.2 Collection of pancreatic cancer cell line-conditioned media 
Clone #3 and Clone #8 monolayers were cultured in T175 cm3 flasks until approximately 60% 
confluent in culture medium. Cells were then washed 3× with serum free (SF) DMEM and 
incubated for 1 hr with SF DMEM. Cells were washed 3× again in SF DMEM, then placed in 
SF DMEM for 72 hrs. At the time of collection, cellular debris was removed by centrifugation 
and filtration through 0.22 µm filter; aliquots were frozen at -80 °C until analysed. 
 
2.3 Invasion assays 
Invasion assays were performed using an adapted method [10]. Matrigel was diluted to 1 mg/ml 
in serum free DMEM. 100 µl of matrigel was placed into each insert (Falcon) (8.0 µm pore size) 
in a 24 well plate (Costar). The coated inserts were incubated overnight at 4 oC. The following 
day, the matrigel was allowed polymerise at 37 oC for 1 hr. The inserts were then washed with 
DMEM, 100 µl of 1x105/100 µl cells in complete DMEM and 100 µl of CM supplemented with 
5 % serum was added onto the insert. 250 µl of total DMEM: 250 µl CM supplemented with 5% 
serum was added to the 24-well. After 24 hours incubation, the inside of the insert was wiped 
with a wet cotton swab. The under surface was gently rinsed with PBS and stained with 0.25% 
crystal violet for 10 minutes, rinsed again with sterile water and allowed to dry. To determine 
total number of invading cells, the inserts were then viewed under the microscope and the 
number of cells per field in 10 random fields, were counted at 200× magnification. The average 
number of cells per field was then multiplied by a factor of 140 (growth area of membrane/field 
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area viewed at 200× magnification (calibrated using a microscope graticule)). Colorimetric 
quantification of invasion was determined by eluting the crystal violet stain solution with 33% 
acetic acid extraction buffer and the absorbance was read with Bio-Tek plate reader (Becton 
Dickinson Labware) at 570 nm and a reference wavelength of 620 nm. The mean values were 
obtained from a minimum of three individual experiments and were subjected to t-tests. All 
experiments were performed in triplicate. 
 
2.4 Sample preparation and protein labelling 
Three 50 ml of CM#3 and CM#8 (3 biological replicates and two technical replicates/CM of cell 
line) were concentrated using 10,000 molecular weight cut-off (Millipore); samples were 
cleaned-up using ready-prep 2D clean-up kit (BioRad). Protein concentration was determined 
using the BCA protein assay kit (Bio-Rad). CM samples were labelled with N-hydroxy 
succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3 and Cy5 [11]. Typically, 50 µg of 
the CM was minimally labelled with 200 pmol of either Cy3 or Cy5 for comparison on the same 
2-D gel. Labelling reactions were performed on ice in the dark for 30 min and then quenched 
with a 50-fold molar excess of free lysine to dye for 10 min on ice. A pool containing equal 
amounts of all samples was also prepared and labelled with Cy2 to be used as a standard on all 
gels to aid image matching and cross-gel statistical analysis. The Cy3 and Cy5 reverse labelling 
reactions (50 µg of each) from each CM sample were mixed and run on the same gels with an 
equal amount (50 µg) of Cy2-labelled standard. 
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2.5 Protein separation by 2-DE and gel imaging 
Immobilised 24 cm linear pH gradient (IPG) strips, pH 3-11, were rehydrated in rehydration 
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer, 50 mM DTT) overnight, 
according to manufactures guidelines. IEF was performed using as IPGphor apparatus (GE 
Healthcare) for 40 kV/h at 20 oC with resistance set at 50 mA. Strips were equilibrated for 20 
min in 50 mM Tris-HCL, pH 8.8, 6 M urea, 30% v/v glycerol, 1% w/v SDS containing 65 mM 
DTT and the for 20 min in the same buffer containing 240 mM iodoacetamide. Equilibrated IPG 
strips were transferred onto 18 x 20 cm 12.5% uniform polyacrylamide gels poured between low 
fluorescence glass plates. Strips were overlaid with 0.5% w/v low melting point agarose in 
running buffer containing bromophenol blue. Gels were run at 2.5 W/gel for 30 min and then 
100 W total at 10 oC. All the images were collected on a Typhoon 9400 Variable Mode Imager 
(GE Healthcare). Statistics and quantification of protein expression were carried out in DeCyder 
software (GE Healthcare). 
 
2.6 Spot digestion and MALDI-TOF analysis 
Excision of protein spots, trypsin digestion and protein identification by MS analysis using an 
Ettan MALDI-TOF Pro (GE Healthcare) was performed. Preparative gels containing 300 µg of 
protein were fixed in 30% v/v methanol, 7.5% v/v acetic acid overnight and washed in water, 
and total protein was detected by post-staining with CBB and Deep purple stain (Molecular 
Probes) for 3 hrs at room temperature. Excess dye was removed by washing twice in water, and 
gels were imaged using a Typhoon 9400 Variable Mode Imager (GE Healthcare) at the 
appropriate excitation and emission wavelengths for the stain. The subsequent gel image was 
imported into the BVA module of DeCyder software and was matched to images generated from 
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DIGE analysis. Spots of interest were selected and confirmed using this software for subsequent 
picking using an Ettan Spot Picker. Gel plugs were placed into a presiliconised 1.5 ml plastic 
tube for destaining, desalting and washing steps. The remaining liquid above the gel plugs was 
removed and sufficient ACN was added in order to cover the gel plugs. Following shrinkage of 
the gel plugs, ACN was removed and the protein containing gel pieces were rehydrated for 5 
min with a minimal volume of 100 mM ammonium bicarbonate. An equal volume of ACN was 
added, and after 15 min of incubation the solution was removed from the gel plugs and the 
samples were dried for 30 min using a vacuum centrifuge. Individual gel pieces were then 
rehydrated in digestion buffer (12.5 ng trypsin per µl of 10% ACN, 40 mM ammonium 
bicarbonate) to cover the gel pieces. Exhaustive digestion was carried out overnight at 37 oC. 
After digestion, the samples were centrifuged at 12000 x g for 10 min using a bench top 
centrifuge. The supernatant was carefully removed from each sample and placed into clean 
plastic tubes. Samples were stored at -80 oC until analysed by M.S. For spectrometric analysis, 
mixtures of tryptic peptides from individual samples were desalted using Millipore C-18 Zip-
Tips (Millipore) and eluted onto the sample plate with the matrix solution (5 mg/ml CHCA in 
50% ACN/0.1% TFA v/v). Mass spectra were recorded using the MALDI-TOF instrument 
operating in the positive reflectron mode at the following parameters: accelerating voltage 20 
kV; and pulsed extraction; on (focus mass 2500). Internal calibration was performed using anti-
analysis peaks at m/z 842.50, m/z 2211.104 and external calibration was performed using Pep4 
mix. The mass spectra were analysed using MALDI evaluation software (GE Healthcare), and 
protein identification was achieved with the PMF Pro-Found search engine. 
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2.7 Western blot 
Protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad). 35 µg of 
protein was separated by 7.5% SDS-PAGE under reducing conditions. Proteins were transferred 
to nitrocellulose membrane. Membranes were blocked at 4 oC overnight in TBS (25mM Tris-
HCl, pH 7.4, 150mM NaCl, 2.7mM KCl) containing 5% (w/v) lowfat milk powder. Membranes 
were probed with monoclonal antibodies, anti-gelsolin (G4896, Sigma) and anti-aldehyde 
dehydrogenase 1A1 (488-501, Calbiochem). Membranes were washed 3x for 5 min with PBS-
Tween-20 (0.5%) and incubated with secondary antibodies, anti-mouse and anti-goat obtained 
from Sigma for 1 hr at RT and washing step repeated. Detection was performed with Luminol 
reagent (Santa Cruz Biotechnology). 
 
2.8 siRNA transfection 
For each set of siRNA transfections carried out, a non-treated control and a scrambled (SCR) 
transfection control (Ambion, # 17010) were used. SiRNA experiments were set up using 2 µl 
NeoFx (Ambion, AM4511), to transfect 30 nM siRNA at a cell density of 3x105 /well/ml of a 6-
well plate. Cells were transfected with two different GSN siRNAs, both of which target variant 
1, isoform a and variant 2, isoform b of GSN (NM_000177 Exon 5, NM_198252 Exon 6: 
Sequence GCAAUCGGUAUGAAAGACUtt (sense), Ambion, #8127) and (NM_000177 Exon 
2, NM_198252 Exon 3: Sequence GCUGAGGAACGGAAAUCUGtt (sense), Ambion, #8031) 
and with three different ALDH1A1 siRNAs targeting the ALDH1A1 isoform (NM_000689 
Exon 11, 12: Sequence GGAACAGUGUGGGUGAAUUtt (sense), Ambion, #106197), 
(NM_000689 Exon 9: Sequence GGAGUGUUGAGCGGGCUAAtt (sense), Ambion, 
#106196), and (NM_000689 Exon 4: Sequence GGGCCGUACAAUACCAAUUtt (sense), 
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Ambion, #106195). After 32 hrs, the media was removed, washed 3× in SF DMEM and 1 ml of 
SF DMEM was added onto the cells. The effects of siRNA silencing were analysed on the SF 
CM after 48 and 72 hrs. SiRNA transfected SF CM was collected, centrifuged and filtered 
through a 0.22 µm filter. SiRNA transfected SF CM was concentrated using 10,000 molecular 
weight cut-off concentrators (Millipore); samples were cleaned-up using ready-prep 2D clean-
up kit (BioRad) and protein concentration was determined using the BCA protein assay kit (Bio-
Rad). Western blot analysis was then carried out to assess efficient transfection. All experiments 
were repeated in triplicate. 
 
2.9 Statistical analysis 
Student’s t-test was used to identify the difference in mean values between treated and non-
treated samples. In siRNA experiments, siRNA scrambled transfected cells were used as control 
compared to siRNA treated samples. This was to ensure no ‘off-target’ effects of the 
transfection procedure. Non-treated controls were used to ensure scrambled siRNA was having 
no effects and to normalise data. A p value of ≤ 0.05 * was deemed significant, p value ≤ 0.01 
** was deemed more significant, p value ≤ 0.005 *** was deemed highly significant. 
 
3.0 Results 
3.1 Factors in conditioned medium alter invasive abilities of pancreatic cancer cell lines 
CM#3 enhanced invasion of Clone #3 by 1.8-fold (p=0.0008) compared to an invasion assay 
control containing fresh medium. Clone #3 containing CM#8 in the invasion assay showed a 
3.33-fold decrease in invasion (p<0.001) (Figure 1 A). Figure 1 B shows that CM#3 
significantly increased the invasion (4.2-fold (p=0.005)) of Clone #8 compared to an invasion 
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assay control containing fresh medium. CM#8 caused a very slight (1.1-fold) decrease in 
invasion of Clone #8 (p=0.7). 
 
3.2 Proteomic analysis of CM#3 and CM#8 by 2-D DIGE MALDI-TOF MS 
Proteins found in CM#3 and CM#8 were analysed by 2-D DIGE. Triplicate biological repeats 
were reverse labelled with Cy3 and Cy5 dyes. All samples used in the experiment were pooled 
and labelled with the internal dye, Cy2. Each sample was compared internally to the same 
standard, to account for any gel-to-gel variation. DeCyder image analysis merged the Cy2, Cy3 
and Cy5 images for each gel and detected spot boundaries for the calculation of normalised 
protein abundance. All paired images were then matched to generate comparative cross-gel 
statistical analysis. Biological variation analysis of these spots showing greater that 1.2-fold 
change in expression with a t-test score of < 0.05, revealed 41 proteins significantly 
differentially regulated between CM #3 versus CM #8. Protein expression maps (PEM) of all 
identified proteins are shown in figure 2 (position number corresponds to table 1 and 2). For 
protein identification, all proteins were digested and identified at least twice from separate gels 
with MALDI-TOF MS. An expectation value of < 0.002 was used for all reported 
identifications, which indicates a 0.2% chance that the identification is random. Table 1 outlines 
the down-regulated proteins in CM#3 compared to CM#8 and table 2 shows the proteins up-
regulated in CM#3 compared to CM#8. 
 
3.3 Gene ontology enrichment analysis 
Using DAVID gene ID tool software (http://david.abcc.ncifcrf.gov), all the proteins 
differentially regulated in our model were converted to their gene IDs. Gene ontology (GO 
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STAT) (http://gostat.wehi.edu.au/cgi-bin/goStat.pl) was then used to classify the proteins and 
their corresponding genes into gene categories. Enrichment of a particular ontology term, for 
significantly expressed genes in response to the process under study, means that the ontology 
term is likely to be involved in the process. In our study, the process refers to factors involved in 
invasion of pancreatic cancer. Using the over-expression function of the software and false 
discovery rate (Benjamini) statistics, 30 GO terms was found significantly enriched in both the 
up-regulated and down-regulated proteins list in CM#3 versus CM#8. The “glycolysis” term 
achieved the highest degree of significance in both the up-regulated and down-regulated gene 
class (p=0.005, p=0.001). In the up-regulated class, “cytoplasm” (p=0.01), “oxidoreductase 
activity” (p=0.01) and “intracellular part”- (including cytoplasmic and nucleus proteins) 
(p=0.03) were highly significant terms. In the down-regulated class, “cytosol” – (no 
membranous or subcellular components) (p=0.007), “actin filament severing” (p=0.03) were 
also significantly enhanced. Figure 3 outlines the top ten ranked functional categories using GO 
terms in the differentially expressed proteins in the pancreatic cancer model.  
 
3.4 Invasion inhibitory role of GSN by siRNA in CM#8 
GSN, a down-regulated protein in CM#3 compared to CM#8 was analysed to assess its 
functional involvement in pancreatic cancer cell invasion. Figure 4 A shows the successful 
knockdown of GSN in CM#8 by two independent siRNA targets relative to control (untreated) 
and siRNA scrambled CM#8. The addition of CM from Clone #8 GSN-siRNA (1) onto Clone 
#8 cells significantly increased the invasive abilities of the cells by 1.3 fold (p=0.01). CM from 
GSN-siRNA (2) treated Clone #8 cells onto Clone #8 also increased the invasiveness of the cells 
1.5 fold (p=0.2) (Figure 4 B).  
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3.5 Invasion enhancement role of ALDH1A1 by siRNA in CM#3 
ALDH1A1, which is up-regulated in CM #3 compared to CM #8, was knocked down in Clone 
#3 to assess its functional role in pancreatic cancer cell invasion. Figure 5 A shows the efficient 
knock down of ALDH1A1 in CM#3 by three independent siRNAs. CM from ALDH1A1-
siRNA treated Clone #3 cells was added into the invasion assay of Clone #3. Reduction of 
ALDH1A1 expression resulted in a significant decrease in invasion of Clone #3. CM#3 
ALDH1A1-siRNA (1) on Clone #3 reduced invasion 4.2-fold (p=0.01), ALDH1A1 siRNA (2) 
decreased invasion 2.7-fold (p=0.003) and ALDH1A1 siRNA (3) also significantly reduced the 
invasive abilities of Clone #3 2.5-fold (p=0.02), compared to the scrambled control (Fig 5 B). 
 
3.6 GSN and ALDH1A1 expression in panel of pancreatic cancer cell lines  
GSN and ALDH1A1 expression was detected western blot in three other human pancreatic 
cancer cell lines, BxPc-3, Panc-1 and AsPc-1 (Figure 6 A). Figure 6 B. shows the relative 
invasive potential of the cell lines. Both BxPc-3 and Panc-1 expressed low levels of GSN 
compared to AsPc-1, which is less invasive. ALDH1A1 expression was stronger in BxPc-3 and 
Panc-1 than in AsPc-1 which corresponds to the high invasive abilities of BxPc-3 and Panc-1.  
 
4.0 Discussion 
In this study, proteins were analysed from culture medium conditioned by Clone #3 and Clone 
#8 in serum-free conditions (SF) (to reduce the abundance of bovine serum proteins in the 
samples). 2D DIGE followed by MALDI-TOF MS analysis of SF CM#3 and CM#8 resulted in 
identification of 41 differentially expressed proteins. Bio-informatic analysis (GO STAT) was 
applied to all differentially abundant proteins between CM#3 and CM#8. Gene ontology (GO 
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STAT) classified the proteins and their corresponding genes into gene categories. Although 
membrane-bound and secreted proteins are more likely to be cleaved and found in the 
circulation [12], our GO STAT analysis determined that most up-regulated and down-regulated 
proteins were involved in glycolysis, cytoplasm, cytosol and intracellular part. Proteins, such as 
heat shock proteins and actins, generally viewed as cytoplasmic, have been increasingly 
implicated in extracellular functions [13, 14]. Eukaryotic protein secretion normally routes 
through the endoplasmatic reticulum (ER) and Golgi, ending up in a secretory vesicle fusing to 
the cell membrane. In addition, recent studies have shown that the non-classical secretory 
pathway works independently of the ER–Golgi network; the secreted proteins do not enter the 
ER and have not been glycosylated [15]. Non-classical secretion by cell lines of the cytosolic 
green fluorescent protein (GFP) was shown experimentally [16]; export was not hampered by 
inhibitors of the classical secretory pathway, such as monensin and brefeldin A. Martin et al. 
[17] also identified many intracellular proteins from both the cytoplasmic and nuclear 
compartments from proteomics analysis of medium conditioned by the prostate cell line, 
LNCaP. During cell culture in serum free conditions, some cells will die, resulting in the release 
of intracellular proteins into the media. These intracellular proteins could serve as viable cancer-
specific markers as cancer cells undergoing death release proteins which can be detected in 
circulation [18]. During our analysis we observed very little difference in the proliferation rate 
of cells grown in serum-free conditions versus normal cell culture, therefore cell death was not a 
major contributor to the expression of intracellular proteins in the CM. Further analysis into the 
possible “secretion” mechanisms of these intracellular proteins would be of interest. 
Two proteins, GSN and ALDH1A1, were chosen for siRNA silencing based on fold difference 
and p-value. GSN is a calcium-binding protein, which binds to and regulates actin filaments. 
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GSN binds to the barbed ends of actin filaments and prevents capping [19]. Severing and 
capping of actin filament enhances the rate of cell motility and migration [20]. Gelsolin is 
located intracellularly in the cytoplasm and mitochondria [21] as well as extracellularly in the 
blood plasma [22]. The intracellular form, termed cytoplasmic, and the secreted form, termed 
plasma GSN, are derived from a single gene by alternative transcription initiation sites and 
differential sequencing [23]. Plasma GSN differs from cytoplasmic GSN, in that it is larger, 
contains 25 extra amino acids at its NH2 terminus, and is more positively charged [24], 
suggesting that it is synthesised more rapidly or catabolised more slowly [25]. Plasma GSN is 
removed from the cells more rapidly, consistent with a secreted protein, and only the plasma 
form of GSN is secreted in HepG2, a human hepatoma-derived cell line. Expression of GSN 
was lowest in the CM of the high invasive cell line, Clone #3, and highest in the CM of the 
poorly invasive Clone #8. RNAi technology was used to study GSN protein function in CM#8. 
Using two independent GSN siRNA target sequences, GSN protein expression was specifically 
down-regulated in Clone #8 cells, resulting in decreased expression of GSN. Addition of CM 
from GSN-siRNA transfected Clone #8 cells into the invasion chamber, increased invasion of 
Clone #8. Our results suggest that GSN has functional effects on invasion in Clone #8 cells. 
Decreased expression of GSN has been detected in several types of human cancers, including 
urinary bladder carcinogenesis [26], NSCLC [27], prostatic adenocarcinoma [28], breast [29] 
and ovarian cancer [30], suggesting a possible role as a tumour suppressor. Our results suggest 
that the invasion-inhibitory effects of CM#8 may be in part due to GSN expression. GSN 
expression suppresses the activation of phospholipase C (PLC)/protein kinase C (PKCs) 
involved in phospholipid signalling pathways, thus inhibiting cell proliferation and 
tumourigenicity [31]. Furthermore, Tanaka et al. [32] functionally knocked down GSN 
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expression by siRNA in the human mammary epithelial cell line, MCF10A, and suggested that 
GSN functions as a switch that controls E- and N-cadherin conversion via the transcription 
factor Snail. GSN knockdown led to an epithelial to mesenchymal transition, characterised by 
fibroblastic morphology, loss of contact inhibition, focus formation in monolayer growth and 
enhanced motility and invasiveness in vitro. Therefore, silencing GSN expression could 
possibly lead to tumour progression. However, GSN over-expression in 56% of breast cancers 
was shown to be associated with over-expression of EGFR and HER2, as well as a more 
aggressive phenotype [33]. High GSN levels have also been identified as a negative prognostic 
factor in pulmonary carcinomas, stage I non-small cell lung carcinomas [34], where they have 
been linked to enhanced cellular motility. In pancreatic cancer, Ni et al [35] found reduced GSN 
expression in 71% (30/42) of pancreatic cancer cases compared to matched control tissues by 
immunohisochemistry. This reduction seemed to be dependent on the ubiquitin-proteasome 
dependent degradation of GSN. However, GSN expression was higher in lymph node positive 
pancreatic cancers compared to lymph node negative tumours. Thompson et al [36] reported 
that high levels of nuclear GSN correlated with reduced patient survival time, signifying re-
emergence of GSN during the most aggressive metastatic stages of pancreatic cancer. Reduction 
in the level of GSN in pancreatic cancer cells decreased the motility of the cells, which differs 
from our results; the up-regulation of motility-modulating actin-capping proteins in pancreatic 
cancer cells may have different consequences for the motility of these cells at different stages of 
the metastatic process [36]. This study found GSN expression in the MiaPaCa-2 cell line, and 
showed that down-regulation of GSN decreased motility. In our model, both cytoplasmic and 
plasma GSN were detected by western blot and 2D-DIGE from the conditioned media of Clone 
#8, the less invasive clonal population of MiaPaCa-2. Clone #8 is a clonal population of 
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MiaPaCa-2, with very different properties from Clone #3, isolated at the same time. 
Furthermore, we found that down-regulation of plasma GSN expression in CM#8 increased 
invasion of Clone #8 cells. Thompson et al [36] detected cytoplasmic/nuclear expression of 
GSN in pancreatic cancer tissue specimens and cytoplasmic GSN in pancreatic cancer cell lines. 
The differences in the GSN isoforms detected between the two studies may explain why 
differing effects on invasion and migration were observed, however further studies are required 
to specifically clarify the roles of cytoplasmic and plasma GSN on migration and invasion in 
pancreatic cancer. A study detailing antibody microarray profiling of combined serum proteins 
associated with pancreatic cancer, showed a significant reduction of plasma GSN in pancreatic 
cancer serum compared to healthy controls [37], and plasma GSN expression was also 
decreased in lung cancer serum by proteomic profiling [38]. The mechanism by which GSN 
stimulates invasion by interacting extracellularly with cancer cells as detailed is not known. To 
further characterise function of GSN in this system, experiments involving addition of 
recombinant GSN protein into CM#3 would be valuable, but highly purified GSN would be 
needed to generate useful results.  
A novel protein identified as promoting the invasive abilities of pancreatic cancer cells is 
aldehyde dehydrogenase 1A1 (ALDH1A1). ALDH1A1 is an enzyme, belonging to the aldehyde 
dehydrogenase family of proteins which are involved in the conversion of aldehydes to their 
corresponding acids by NAD(P)+ dependent reactions [39]. ALDH1A1 is a cytosolic enzyme 
found in many tissues, including brain [40] and red blood cells [41]. ALDH1A1 expression has 
also been implicated in drug resistance, as ALDH1A1 levels were higher in metastatic tumours 
that did not respond to cyclophosphamide-based treatment than those that did respond to the 
regime [42]. ALDH1A1 expression has also been reported in the lung cancer cell line, A549, 
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where its expression along with ALDH1A3 was knocked down by RNAi and implicated in 
cyclophosphamide resistance [43]. Jelski et al. [44] also found that ALDH is expressed in 
pancreatic cancer cells and furthermore ALDH could also be detected in the sera of pancreatic 
cancer patients, although not significantly different between pancreatic cancer patients and 
healthy controls [45]. 
ALDH1A1 is highly expressed in CM#3 compared to CM#8. ALDH1A1 expression was 
reduced in CM#3 through siRNA targeting three independent sequences of the ALDH1A1 gene. 
Addition of CM from ALDH1A1-siRNA transfected Clone #3 cells into the invasion chamber 
reduced invasion of Clone #3 cells. This is the first time that ALDH1A1 has been reported as a 
protein involved in pancreatic cancer cell invasion. Further research will be required to 
determine its role in the clinical setting.  
The expression of GSN and ALDH1A1 determined by western blot in the human pancreatic 
cancer cell lines, BxPc-3, Panc-1 and AsPc-1 corresponded to the invasive properties of the 
cells. A larger panel of pancreatic cancer cell lines would be required to confirm the link 
between expression of these proteins and invasion status in pancreatic cancer. Han et al [46] 
found that GSN mRNA is expressed at low levels in a panel of nine pancreatic cancer cell lines 
compared to normal pancreas using cDNA microarrays. 
In conclusion, identification of released proteins from cancer cell lines may serve as an efficient 
method in the establishment of a panel of potential therapeutic targets and biomarkers 
correlating to invasion/metastatic cascade of pancreatic cancer. Future work will include 
examining the sera of pancreatic cancer patients to further demonstrate if GSN and ALDH1A1 
have a diagnostic potential as biomarkers for pancreatic adenocarcinoma. 
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Figure legends 
Figure 1 A. Invasion assays of Clone #3 under control conditions and containing CM#3 and 
CM#8 in the invasion insert. B. Invasion assays of Clone #8 under control conditions and 
containing CM#3 and CM#8 in the invasion insert. The total number of invading cells was 
determined by counting the number of cells per field in 10 random fields, at 200× magnification. 
The average number of cells per field was then multiplied by a factor of 140 (growth area of 
membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)). 
Insert: Colorimetric relative quantification of invading cells was also determined by elution of 
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inserts with 0.33% acetic acid and spectrophotometrically quantified. All experiments were 
performed in triplicate. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 Student’s t-test. 
 
Figure 2 Protein expression map (PEM) of differentially regulated proteins in the comparison of 
CM#3 versus CM#8. All protein numbers correspond to table 1 and 2. 
Figure 3. Term-ranking GO categories. Representation of the 10 top-ranked functional 
categories, using GO terms that are enriched in all significantly differentially expressed proteins 
identified between CM#3 and CM#8.  
 
Figure 4 A. Western blot of two independent target siRNA-GSN knockdown in CM#8. Bip 
antibody was used to demonstrate even loading between the samples. B. Invasion assay of Clone 
#8 cells with the addition of CM#8 untreated control, CM#8 scrambled siRNA , CM#8 treated 
with GSN-siRNA (1) and CM#8 treated with GSN-siRNA (2) (n=3).  The total number of 
invading cells was determined by counting the number of cells per field in 10 random fields, at 
200× magnification. The average number of cells per field was then multiplied by a factor of 
140 (growth area of membrane/field area viewed at 200× magnification (calibrated using a 
microscope graticule)). Insert: Colorimetric relative quantification of invading cells was also 
determined by elution of inserts with 0.33% acetic acid and spectrophotometrically 
quantified.Experiments performed in triplicate. Statistics; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.005. 
 
Figure 5 A. Western blot of ALDH1A1 knockdown in CM#3 untreated control, scrambled, 
siRNA ALDH1A1 (1), siRNA ALDH1A1 (2) and siRNA ALDH1A1 (3). B. Invasion assay of 
Clone #3 with addition of CM#3 media (control), CM#3 media with scrambled siRNA, CM#3 
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treated with ALDH1A1 siRNA (1), CM#3 treated with ALDH1A1 siRNA (2), CM#3 treated 
with ALDH1A1 siRNA (3) (n=3).  The total number of invading cells was determined by 
counting the number of cells per field in 10 random fields, at 200× magnification. The average 
number of cells per field was then multiplied by a factor of 140 (growth area of membrane/field 
area viewed at 200× magnification (calibrated using a microscope graticule)). Insert: 
Colorimetric relative quantification of invading cells was also determine by elution of inserts 
with 0.33% acetic acid and spectrophotometrically quantified. The total number of invading 
cells were stained with 0.25% crystal violet, eluted with 0.33% acetic acid and 
spectrophotometrically quantified, to determine the relative number of invading cells. 
Experiments performed in triplicate. Magnification, 200x. Scale bar, 200µm. Statistics; * ≤ 0.05, 
** ≤ 0.01, *** ≤ 0.005. 
 
Figure 6 A. Western blot of GSN and ALDH1A1 expression in pancreatic cancer cell lines, 
BxPc-3, Panc-1 and AsPc-1. β-actin was used as loading control. B. Invasion assay of BxPc-3, 
Panc-1 and AsPc-1. The total number of invading cells was determined by counting the number 
of cells per field in 10 random fields, at 200× magnification. The average number of cells per 
field was then multiplied by a factor of 140 (growth area of membrane/field area viewed at 200× 
magnification (calibrated using a microscope graticule)). Insert: Colorimetric relative 
quantification of invading cells was also determined by elution of inserts with 0.33% acetic acid 
and spectrophotometrically quantified. Experiments performed in triplicate. 
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Table 1. 2D DIGE and MALDI-TOF MS identification of down-regulated proteins in the conditioned media of the invasive Clone #3
No Protein name Gene 
symbol
Protein AC 
number
Theoretical 
pI/Mw
% 
Coverage
Fold 
change
Molecular function
1 Gelsolin isoform b (a) GSN gi|38044288| 5.6/80.9 17.9 -21.0 *** Structural constituent of the 
cytoskeleton
2 Gelsolin isoform b (b) GSN gi|38044288| 5.6/80.9 24.4 -15.2 *** Structural constituent of the 
cytoskeleton
3 Gelsolin isoform b (c) GSN gi|38044288| 5.6/80.9 18.6 -10.7 *** Structural constituent of the 
cytoskeleton
4 Gelsolin isoform b (f) GSN gi|38044288| 5.6/80.9 15.2 -6.4 *** Structural constituent of the 
cytoskeleton
5 Gelsolin isoform b (d) GSN gi|38044288| 5.6/80.9 18.3 -3.8 *** Structural constituent of the 
cytoskeleton
6 Gelsolin isoform b (g) GSN gi|38044288| 5.6/80.9 18.5 -3.4 *** Structural constituent of the 
cytoskeleton
7 Gelsolin (amyloidosis: Finnish type) GSN gi|55960299| 5.9/86.0 9.5 -2.5 *** Structural constituent of the 
cytoskeleton
8 Pro-MMP-2TIMP2 complex TIMP2 gi|22218678| 6.5/22.4 30.9 -1.8 *** ECM structural constituent
9 Beta actin (a) ACTB gi|15277503| 5.6/40.5 36.6 -1.7 *** Structural constituent of the 
cytoskeleton
10 Nucleoside-diphosphate kinase 2 isoform NDPK2 gi|66392203| 9.3/30.5 21.7 -1.7 ** Transcription factor 
activity
11 Beta actin (c) ACTB gi|15277503| 5.6/40.5 24.4 -1.6 *** Structural constituent of the 
cytoskeleton
Table
12 Proteasome activator Reg(Alpha) PSME1 gi|2780883| 7.1/16.3 44.3 -1.5 *** Ubiquitin-specific protease 
activity
13 Beta actin (b) ACTB gi|15277503| 5.6/40.5 24.2 -1.5 *** Structural constituent of the 
cytoskeleton
14 Heat shock protein 90-alpha (HSP86) HSP86 gi|92090606| 4.9/85.0 24.5 -1.5 *** Chaperone activity
15 Phosphoglycerate kinase 1 (a) PGK1 gi|48145549| 8.6/44.9 25.7 -1.4 *** Catalytic activity
16 Thioredoxin peroxidase PRDX2 gi|9955016| 5.7/21.6 28.4 -1.4 *** Peroxidase activity
17 Phosphoglycerate kinase 1 (b) PGK1 gi|48145549| 8.6/44.9 25.7 -1.4 *** Catalytic activity
18 Phosphoglycerate kinase 1 (c) PGK1 gi|48145549| 8.6/44.9 27.3 -1.4 *** Catalytic activity
19 Heat shock 70kDa protein 8 isoform 2 (b) HSPA8 gi|62896815| 5.6/53.6 16.8 -1.3 *** Heat shock protein activity
20 Beta actin (d) ACTB gi|15277503| 5.6/40.5 27.3 -1.3 *** Structural constituent of the 
cytoskeleton
21 NM23-H1 NME1 gi|29468184| 5.4/19.8 27.1 -1.3 *** Catalytic activity
22 Triosephosphate isomerase TPI1 gi|999893| 6.5/26.8 29.0 -1.3 *** Isomerase activity
23 Heat shock 70kDa protein 8 isoform 2 (a) HSPA8 gi|62896815| 5.6/53.6 28.8 -1.3 *** Heat shock protein activity
24 S-adenosylhomocysteine hydrolase AHCY gi|178277| 6.0/48.2 10.6 -1.3 *** Hydrolase activity
25 Malate dehydrogenase cytosolic MDH1 gi|7431153| 5.9/36.6 20.1 -1.2 *** Catalytic activity
26 Heat shock 70kDa protein 8 isoform 2 
variant (c)
HSPA8 gi|62896815| 5.6/53.6 19.7 -1.2 *** Heat shock protein activity
27 Nucleoside phosphorylase NP gi|58176568| 6.5/32.2 36.1 -1.2 *** Phosphorylase activity
Table 2. 2D DIGE and MALDI-TOF MS identification of up-regulated proteins in the conditioned media of the invasive Clone #3
No Protein name Gene 
symbol
Protein AC 
number
Theor
pI/Mw
% 
Coverage
Fold 
change
Molecular function
28 Capping protein, muscle Z line, alpha 1 CAPZA1 gi|12652789| 5.4/33.0 39.9 1.2 *** Structural molecule activity
29 Beta actin (g) ACTB gi|15277503| 5.6/40.5 30.6 1.2 * Structural constituent of the 
cytoskeleton
30 Beta actin (f) ACTB gi|15277503| 5.6/40.5 24.4 1.2 * Structural constituent of the 
cytoskeleton
31 Glycerate-3-phosphate dehydrogenase GAPDH gi|31645| 8.4/36.2 19.4 1.2 ** Catalytic activity
32 Beta actin (e) ACTB gi|15277503| 5.6/40.5 24.5 1.2 * Structural constituent of the 
cytoskeleton
33 Galectin-1 LGALS1 gi|56554350| 5.1/14.8 38.1 1.3 *** Receptor binding
34 Mu-protocadherin isoform MUCDHL gi|62020550| 4.8/88.4 18.2 1.3 *** Cell adhesion molecule 
acitivity
35 Pi glutathione transferase GSTP1 gi|34811304| 5.7/23.4 36.4 1.3 *** Glutathione transferase 
activity
36 Elongation factor EEF1A1 gi|15277711| 9.3/46.5 12.1 1.4 *** Translation regulator 
activity
37 Alpha enolase (b) ENO1 gi|2661039| 7.0/47.4 28.6 1.5 *** Catalytic activity
38 Peroxiredoxin 1 PRDX1 gi|55959887| 6.4/19.1 53.2 1.5 *** Peroxidase activity
39 Alpha enolase (a) ENO1 gi|2661039| 7.0/47.4 15.5 1.5 *** Catalytic activity
40 Mitochondrial malate dehydrogenase MDH2 gi|12804929| 9.4/35.9 37.0 1.6 *** Catalytic activity
41 Aldehyde dehydrogenase 1A1 ALDH1A1 gi|2183299| 6.3/55.4 18.4 21.0 *** Aldehyde dehydrogenase 
activity
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from the sequence of the protein in the database. Isoforms of 
the same protein are referred to as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered by the matched peptides. 
Statistical analysis between replicates is referred to as; * p ≤ 0.05, *** p ≤ 0.01, *** p ≤ 0.005.
